In a previous phase II randomized controlled clinical study, Tivantinib, a highly selective c-Met inhibitor, improved median time to progression and OS time in patients with Met-high advanced HCC compared with placebo (Santoro et al., 2013)
It holds regulatory approval in Russia for stroke recovery and cognitive disorders, which gives it a unique position among these nomineesit is the only compound on the list with any form of governmental approval for clinical use, albeit outside Western regulatory frameworks
References Frontiers in Endocrinology (2021) Progress on the Function and Application of Thymosin 4 Annals of the New York Academy of Sciences Thymosin 4: roles in development, repair, and engineering of the cardiovascular system Frontiers in Pharmacology (2022) Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 HSS Journal (2025) Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review Current Pharmaceutical Design (2018) Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract Journal of Orthopaedic Surgery and Research (2019) BPC 157 and its effects on tendon healing CDC (2024) Vaccine Administration: Subcutaneous (SUBCUT) Injection NCBI Bookshelf (2023) Administration of Parenteral Medications Nursing Skills CDC (NCHS) Laboratory Procedure Manual: C-Peptide in Serum (storage guidelines) Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Supernatants were collected and protein content was determined using the BCA assay (Thermo Fisher Scientific)
103 ParkW
Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women
